Management of retinitis pigmentosa by Wharton’s jelly-derived mesenchymal stem cells: prospective analysis of 1-year results

Özmert, Emin; Arslan, Ümüt

doi:10.1186/s13287-020-01870-w

Cited by 40 publications

(33 citation statements)

References 81 publications

(128 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there was no effect detected on ERG, mfERG, or microperimetry [25]. Another study based on 34 RP eyes injected with allogenic umbilical cord Wharton's jelly-derived MSCs into the subtenon space presented significant improvement in BCDVA and 24-2 visual field observed in the period between 6 and 12 months after the intervention [26]. Unlike our study, the significant improvement in BCDVA at the 12-month visit was detected only in autosomal dominant and autosomal recessive forms of RP [26].…”

Section: Discussionmentioning

confidence: 96%

Long-Term Effects of Adjuvant Intravitreal Treatment with Autologous Bone Marrow-Derived Lineage-Negative Cells in Retinitis Pigmentosa

Wiącek

Gosławski

Grabowicz

et al. 2021

Stem Cells International

View full text Add to dashboard Cite

Background. Autologous bone marrow-derived lineage-negative (Lin−) cells present antiapoptotic and neuroprotective activity. The aim of the study was to evaluate the safety and efficacy of novel autologous Lin− cell therapy during a 12-month follow-up period. Methods. Intravitreal injection of Lin− cells in 30 eyes with retinitis pigmentosa (RP) was performed. The fellow eyes (FEs) were considered control eyes. Functional and morphological eye examinations were performed before and 1, 3, 6, 9, and 12 months after the injection. Results. Patients whose symptoms started less than 10 years ago gained 14 ± 10 letters, while those with a longer disease duration gained 2.86 ± 8.54 letters compared to baseline at the 12-month follow-up ( p = 0.021 ). There were significantly higher differences in response densities of P 1 -wave amplitudes in the first ring of multifocal ERGs in treated eyes than FE recordings in all follow-up points were detected. Accordingly, the mean deviation in 10-2 static perimetry improved significantly in the treated eyes compared with fellow eyes 12 months after the procedure. The QoL scores improved significantly and lasted until the 9-month visit. Conclusion. Lin− cell-based therapy is safe and effective, especially for a well-selected group of RP patients who still maintained good function of the foveal cones.

show abstract

Section: Discussionmentioning

confidence: 96%

Long-Term Effects of Adjuvant Intravitreal Treatment with Autologous Bone Marrow-Derived Lineage-Negative Cells in Retinitis Pigmentosa

Wiącek

Gosławski

Grabowicz

et al. 2021

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…In this study, we utilized the autologous BM-MSCs to avert the host-versus-graft rejection which might occur after an allogeneic transplantation. However, recently, remarkable advancements were reported in the use of allogeneic transplantation of Wharton’s jelly-derived MSCs, which showed promising safety and efficacy results in clinical trials as a candidate cell therapy for retinitis pigmentosa [ 25 , 26 ]. There are several administration routes of MSCs that had been validated.…”

Section: Discussionmentioning

confidence: 99%

“…The MSCs administered via this route hardly pass the internal limiting membrane of the retina [ 28 ], but the secreted paracrine factors from MSCs could [ 29 ]. Recently, a phase 3 clinical study reported the superior safety and efficacy profile of subtenon MSC injection since this cavity is hypovascular and the secreted growth factors could pass through the choroid to the subretinal space [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Intravitreal autologous mesenchymal stem cell transplantation: a non-randomized phase I clinical trial in patients with retinitis pigmentosa

et al. 2021

View full text Add to dashboard Cite

Background Retinitis pigmentosa (RP) is a progressive inherited retinal disease with great interest for finding effective treatment modalities. Stem cell-based therapy is one of the promising candidates. We aimed to investigate the safety, feasibility, and short-term efficacy of intravitreal injection of bone marrow-derived mesenchymal stem cells (BM-MSCs) in participants with advanced stage RP. Methods This non-randomized phase I clinical trial enrolled 14 participants, categorized into three groups based on a single dose intravitreal BM-MSC injection of 1 × 106, 5 × 106, or 1 × 107 cells. We evaluated signs of inflammation and other adverse events (AEs). We also assessed the best corrected visual acuity (BCVA), visual field (VF), central subfield thickness (CST), and subjective experiences. Results During the 12-month period, we noticed several mild and transient AEs. Interestingly, we found statistically significant improvements in the BCVA compared to baseline, although they returned to the baseline at 12 months. The VF and CST were stable, indicating no remarkable disease progression. We followed 12 participants beyond the study period, ranging from 1.5 to 7 years, and observed one severe but manageable AE at year 3. Conclusion Intravitreal injection of BM-MSCs appears to be safe and potentially effective. All adverse events during the 12-month period required observation without any intervention. For the long-term follow-up, only one participant needed surgical treatment for a serious adverse event and the vision was restored. An enrollment of larger number of participants with less advanced RP and long-term follow-up is required to evaluate the safety and efficacy of this intervention. Trial registration ClinicalTrials.gov, NCT01531348. Registered on February 10, 2012

show abstract

“…Therefore, other routes of MSC application have been tested. These approaches include subretinal application [ 113 ], suprachoroidal delivery [ 114 ] and subtenon injection [ 115 ].…”

Section: Possible Problems and Limitations Associated With Msc-basmentioning

confidence: 99%

“…A similar improvement in visual function after the injection of autologous BM-MSC was observed in patients with optic nerve diseases and nonarteritic ischemic optic neuropathy [ 168 , 169 ]. In addition to the application of autologous BM-MSC, Wharton’s jelly-derived MSC transplantation improved outer retinal thickness and visual acuity in patients with RP in phase 3 clinical study [ 115 ].…”

Section: Clinical Trials Using Mscs For Retinal Diseasesmentioning

confidence: 99%

Mesenchymal Stem Cell-Based Therapy for Retinal Degenerative Diseases: Experimental Models and Clinical Trials

Holáň

Palacká

Heřmánková

2021

Cells

View full text Add to dashboard Cite

Retinal degenerative diseases, such as age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy or glaucoma, represent the main causes of a decreased quality of vision or even blindness worldwide. However, despite considerable efforts, the treatment possibilities for these disorders remain very limited. A perspective is offered by cell therapy using mesenchymal stem cells (MSCs). These cells can be obtained from the bone marrow or adipose tissue of a particular patient, expanded in vitro and used as the autologous cells. MSCs possess potent immunoregulatory properties and can inhibit a harmful inflammatory reaction in the diseased retina. By the production of numerous growth and neurotrophic factors, they support the survival and growth of retinal cells. In addition, MSCs can protect retinal cells by antiapoptotic properties and could contribute to the regeneration of the diseased retina by their ability to differentiate into various cell types, including the cells of the retina. All of these properties indicate the potential of MSCs for the therapy of diseased retinas. This view is supported by the recent results of numerous experimental studies in different preclinical models. Here we provide an overview of the therapeutic properties of MSCs, and their use in experimental models of retinal diseases and in clinical trials.

show abstract

Management of retinitis pigmentosa by Wharton’s jelly-derived mesenchymal stem cells: prospective analysis of 1-year results

Cited by 40 publications

References 81 publications

Long-Term Effects of Adjuvant Intravitreal Treatment with Autologous Bone Marrow-Derived Lineage-Negative Cells in Retinitis Pigmentosa

Long-Term Effects of Adjuvant Intravitreal Treatment with Autologous Bone Marrow-Derived Lineage-Negative Cells in Retinitis Pigmentosa

Intravitreal autologous mesenchymal stem cell transplantation: a non-randomized phase I clinical trial in patients with retinitis pigmentosa

Mesenchymal Stem Cell-Based Therapy for Retinal Degenerative Diseases: Experimental Models and Clinical Trials

Contact Info

Product

Resources

About